Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;7(3):305–316. doi: 10.1111/j.1527-3458.2001.tb00201.x

Adrogolide HCl (ABT‐431; DAS‐431), a Prodrug of the Dopamine D1 Receptor Agonist, A‐86929: Preclinical Pharmacology and Clinical Data

William J Giardina 1,✉, Michael Williams 2
PMCID: PMC6741696  PMID: 11607045

ABSTRACT

Adrogolide (ABT‐431; DAS‐431) is a chemically stable prodrug that is converted rapidly (<1 min) in plasma to A‐86929, a full agonist at dopamine D1 receptors. In in vitro functional assays, A‐86929 is over 400 times more selective for dopamine D1 than D2 receptors. In rats with a unilateral loss of striatal dopamine, A‐86929 produces contralateral rotations that are inhibited by dopamine D1 but not by dopamine D2 receptor antagonists. Adrogolide improves behavioral disability and locomotor activity scores in MPTP‐lesioned marmosets, a model of Parkinson's disease (PD), and shows no tolerance upon repeated dosing for 28 days.

In PD patients, intravenous (i.v.) adrogolide has antiparkinson efficacy equivalent to that of L‐DOPA with a tendency towards a reduced liability to induce dyskinesia. The adverse events associated with its use were of mild‐to‐moderate severity and included injection site reaction, asthenia, headache, nausea, vomiting, postural hypotension, vasodilitation, and dizziness.

Adrogolide can also attenuate the ability of cocaine to induce cocaine‐seeking behavior and does not itself induce cocaine‐seeking behavior in a rodent model of cocaine craving and relapse. In human cocaine abusers, i.v. adrogolide reduces cocaine craving and other cocaine‐induced subjective effects. The results of animal abuse liability studies indicate that adrogolide is unlikely to have abuse potential in man. Adrogolide has also been reported to reverse haloperidol‐induced cognitive deficits in monkeys, suggesting that it may be an effective treatment for the cognitive dysfunction associated with aging and disease.

Adrogolide undergoes a high hepatic “first‐pass” metabolism in man after oral dosing and, as a result, has a low oral bioavailability (±4%). This limitation may potentially be circumvented by oral inhalation formulations for intrapulmonary delivery that greatly increase the bioavailability of adrogolide. As the first full dopamine D1 receptor agonist to show efficacy in PD patients and to reduce the craving and subjective effects of cocaine in cocaine abusers, adrogolide represents an important tool in understanding the pharmacotherapeutic potential of dopamine D1 receptor agonists.

Keywords: ABT‐431, Adrogolide, Antiparkinson drug, DAS‐431, Dopamine agonist, Dopamine receptor, Parkinson's disease

Full Text

The Full Text of this article is available as a PDF (143.8 KB).

References

  • 1. Andersen PH, Nielsen EB, Scheel‐Kruger J, Jansen JA, Hohlweg R. Thienopyridine derivatives identified as the first selective, full efficacy, dopamine D1 receptor agonists. Eur J Pharmacol 1987;137:291–292. [DOI] [PubMed] [Google Scholar]
  • 2. Asin KE, Domino EF, Nikkel A, Shiosaki K. The selective dopamine D1 receptor agonist A‐86929 maintains efficacy with repeated treatment in rodent and animal primate models of Parkinson's disease. J Pharmacol Exp Ther 1997;281:454–459. [PubMed] [Google Scholar]
  • 3. Bertz R, Wong C, Lafnitzegger K, Willems R, Wright S. The pharmacokinetics and safety of a selective dopamine D1 receptor agonist, A‐86929, after intravenous administration of ABT‐431 to Parkinson's disease patients. Pharm Res 1997;14:S610. [Google Scholar]
  • 4. Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase TN. Selective D1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Trans 1987;68:41–50. [DOI] [PubMed] [Google Scholar]
  • 5. Britton DR, Curzon P, Mackenzie RG, Kebabian JW, Williams JEG, Kerkman D. D1 dopamine receptor agonists indice forelimb clonus. Soc Neurosci Abstr 1991;17:638. [Google Scholar]
  • 6. Calne D. Early idiopathic parkinsonism: Initiation and optimization of treatment. Clin Neuropharmacol 1994;17:S14–S18. [PubMed] [Google Scholar]
  • 7. Castner SA, Williams GV, Goldman‐Rakic PS. Reversal of antipsychotic‐induced working memory deficits by short‐term dopamine D1 receptor stimulation. Science 2000;287:2020–2022. [DOI] [PubMed] [Google Scholar]
  • 8. Chen Y, Engh K, Doil C, et al. Gingival adhesive systems for sustained‐release of ABT‐431. Proceeding of 25th International Symposium on Controlled Release of Bioactive Materials, June 21–24. Controlled Release Soc Abstr 1998. [Google Scholar]
  • 9. Giardina WJ, Williams M, Porsolt R, Roux S. ABT‐431, a prodrug of the dopamine D1 receptor agonist A‐86929, is inactive in conditioned place preference and self‐administration tests of abuse liability. Soc Neurosci Abstr 2000;26:748. [Google Scholar]
  • 10. Gingrich JA, Caron MG. Recent advances in the molecular biology of dopamine receptors. Ann Rev Neurosci 1993;16:299–321. [DOI] [PubMed] [Google Scholar]
  • 11. Grondin R, Medard PJ, Britton DR, Shiosaki K. Potential therapeutic use of the selective D1 receptor agonist A‐86929: An acute study in parkinsonian levodopa‐primed monkeys. Neurology 1997;49:421–426. [DOI] [PubMed] [Google Scholar]
  • 12. Hagen JJ, Middlemiss DN, Asharpe PC, Poste GH. Parkinson's disease: Prospects for improving drug therapy. Trends Pharmacol Sci 1997;18:156–163. [DOI] [PubMed] [Google Scholar]
  • 13. Haney M, Foltin RW, Fischman MW. Effects of pergolide on cocaine self‐administration in men and women. Psychopharmacology 1998;137:15–24. [DOI] [PubMed] [Google Scholar]
  • 14. Haney M, Collins, ED , Ward AS, Foltin RW, Fischman MW. Effect of a selective dopamine D1 agonist (ABT‐431) on smoked cocaine self‐administration in humans. Psychopharmacology 1999;143:102–110. [DOI] [PubMed] [Google Scholar]
  • 15. Heikkila RE, Sonsalla PK, Duvoisin R. Biochemical models of Parkinson's disease In: Neuromethods: Drugs as Tools in Neurotransmitter Research. Boulton AA, Baker GB, Juorio AV, Eds. Clifton , New York : Humana Press, 1989:351–384. [Google Scholar]
  • 16. Kebabian JW, Britton DR, DeNinno MP, et al. A‐77636: A potent and selective dopamine D1 receptor agonist with anti‐parkinsonian activity in marmosets. Eur J Pharmacol 1992;229:203–209. [DOI] [PubMed] [Google Scholar]
  • 17. Kranzler HR, Bauer LO. Bromocriptine and cocaine cue reactivity in cocaine‐dependent patients. Br J Addict 1992;87:1537–1548. [DOI] [PubMed] [Google Scholar]
  • 18. Levin FR, McDowell D, Evans SM, Brooks D, Spano C, Nunes EV. Pergolide mesylate for cocaine abuse: A controlled preliminary trial. Am J Addict 1999;8:120–127. [DOI] [PubMed] [Google Scholar]
  • 19. Malcolm R, Moore BJ, Sutherland S. Dose response effects of pergolide in the treatment of cocaine dependence. NIDA Res Monograph Series 1999;279:55. [Google Scholar]
  • 20. Marsden C. Problems with long‐term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994;17:S32–S44. [PubMed] [Google Scholar]
  • 21. Meyer ME, Shults JM. Dopamine D1 receptor family agonists, SK&F38393, SK&F77434 and SK&F82958, differentially affect locomotor activities in rats. Pharmacol Biochem Behav 1993;46:269–274. [DOI] [PubMed] [Google Scholar]
  • 22. Michaelides, MR , Hong Y, DiDomenico S, et al. (5aR,11bS)‐4,5,5a,6,7,11b‐Hexahydro‐2‐propyl‐3‐thia‐5‐azacyclopent‐1‐ena[c]‐phenanthrene‐9,10‐diol (A‐86929): A potent and selective agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT‐431). J Med Chem 1995;38:3445–3447. [DOI] [PubMed] [Google Scholar]
  • 23. Okumu FW, Lee R‐Y, Blanchard JD, et al. Evaluation of the AERx pulmonary delivery system for systemic delivery of a selective D1 agonist. Pharm Sci Abstr 1998;1:S141. [DOI] [PubMed] [Google Scholar]
  • 24. Preston KL, Sullivan JT, Strain EC, Bigelow GE. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther 1992;262:279–291. [PubMed] [Google Scholar]
  • 25. Rascol O, Blin O, Thalamas C, et al. ABT‐431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease. Ann Neurol 1999;45:736–741. [DOI] [PubMed] [Google Scholar]
  • 26. Rascol O, Nutt J, Blin O, et al. Induction by dopamine D1 receptor agonist ABT‐431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 2001;58:249–254. [DOI] [PubMed] [Google Scholar]
  • 27. Self DW. Neural substrates of drug craving and relapse in drug addiction. Ann Med 1998;30:379–389. [DOI] [PubMed] [Google Scholar]
  • 28. Self DW, Stein L. The D1 agonists SKF 82958 and SKF 77434 are self‐administered by rats. Brain Res 1992;582:349–352. [DOI] [PubMed] [Google Scholar]
  • 29. Self DW, Baarnhart WJ, Lehman DA, Nestler EJ. Opposite modulation of cocaine‐seeking behavior by D1 and D2‐like dopamine receptor agonists. Science 1996;271:1586–1589. [DOI] [PubMed] [Google Scholar]
  • 30. Self DW, Karanian DA, Spencer JJ. Effects of the novel D1 dopamine receptor agonist ABT‐431 on cocaine self‐administration and reinstatement. Ann NY Acad Sci 2000;909:133–144. [DOI] [PubMed] [Google Scholar]
  • 31. Shiosaki K, Asin KE, Britton DR, et al. Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D1 receptor agonists A‐86929 and ABT‐431. Eur J Pharmacol 1996;317:183–190. [DOI] [PubMed] [Google Scholar]
  • 32. Shiosaki K, Jenner P, Asin KE, et al. ABT‐431: The diacetyl prodrug of A‐86929, a potent and selective dopamine D1 receptor agonist: In vitro characterization and effects in animal models of parkinson's disease. J Pharmacol Exp Ther 1996;276:150–160. [PubMed] [Google Scholar]
  • 33. Stacy M, Jankovic J. Current approaches in the treatment of Parkinson's disease. Ann Rev Med 1993;43:431–440. [DOI] [PubMed] [Google Scholar]
  • 34. Temlett JA, Quinn, NP , Jenner PG, et al. Antiparkinsonian activity of CY 208–243, a partial D1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease. Mov Disord 1989;4:261–265. [DOI] [PubMed] [Google Scholar]
  • 35. Water CM, Hunt SP, Jenner P, Marsden CD. An immunohistochemical study of the acute and long‐term effects of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in the marmoset. Neuroscience 1987;23:1025–1039. [DOI] [PubMed] [Google Scholar]
  • 36. Woolverton WL. Goldberg LI, Ginos JZ. Intravenous self‐administration of dopamine receptor agonists by rhesus monkeys. J Pharmacol Exp Ther 1984;230:678–683. [PubMed] [Google Scholar]
  • 37. Zheng Y, Marsh KC, Bertz RJ, El‐Shourbagy T, Adjei AL. Pulmonary delivery of a dopamine D1 agonist, ABT‐431, in dogs and humans. Int J Pharm 1999;191:131–140. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES